Clinical Trials - Phase I

Found 19,649 articles

• Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

  5/25/2023

  Syros Pharmaceuticals announced new clinical data from the Phase 1/1b clinical trial evaluating SY-5609, its highly selective and potent inhibitor of CDK7, in patients with relapsed/refractory pancreatic ductal adenocarcinoma, HR+ breast cancer and other solid tumors.

• Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

  5/25/2023

  Alaunos Therapeutics, Inc. announced that the Company will present early translational data from the first three patients treated in its ongoing TCR-T Library Phase 1/2 trial at the 2023 American Society of Clinical Oncology Annual Meeting taking place June 2-6, 2023, at the McCormick Place Convention Center in Chicago.

• Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors

  5/25/2023

  Xilio Therapeutics, Inc. announced preliminary data from its Phase 1 clinical trial evaluating XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors.

• Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

  5/25/2023

  Bolt Biotherapeutics, Inc. announced the data from its Phase 1 dose-escalation clinical trial of BDC-1001 that will be presented in a poster session at the American Society of Clinical Oncology 2023 Annual Meeting, being held at McCormick Place in Chicago, Illinois and virtually from June 2-6, 2023.

• I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

  5/25/2023

  I-Mab announced encouraging results from the Phase 1b/2 study evaluating uliledlimab, the Company's proprietary and highly differentiated CD73 antibody, in combination with toripalimab, a PD-1 antibody, in patients with treatment-naïve advanced non-small cell lung cancer, and exploring the potential value of CD73 expression as a predictive biomarker.

• Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting

  5/25/2023

  Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer cell-based therapies, announced the presentation of initial data from the dose-escalation stage of its ongoing Phase 1/2 clinical trial of AB-101.

• Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01

  5/25/2023

  Evaxion Biotech A/S to present promising clinical data from its EVX-01 Phase 1 clinical trial in metastatic melanoma on June 3, at the 2023 ASCO annual meeting, in Chicago, Illinois.

• AffyImmune Therapeutics Announces Positive Safety and Early Efficacy Results from Phase 1 Study of AIC100 CAR T Cells in Anaplastic and Advanced Thyroid Cancers at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/25/2023

  AffyImmune Therapeutics, Inc. announced positive safety and early efficacy results from a Phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers, which will be presented at the 2023 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, on June 5, 2023.

• Tvardi Therapeutics Announces Presentation of Data from the Phase 1 Trial of TTI-101, a STAT3 inhibitor, in Advanced Solid Tumors at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

  5/25/2023

  Tvardi Therapeutics, Inc. (“Tvardi”) will publicly present, for the first time, clinical results from the Phase 1 study of TTI-101, a STAT3 inhibitor, in relapsed/refractory patients with advanced solid tumors, at the upcoming American Society of Clinical Oncology (ASCO) 2023 annual meeting taking place June 2-6, 2023 in Chicago, IL.

• 

  Wave’s Antisense ALS Therapy Is Company’s Latest Miss

  5/24/2023

  Wave will discontinue development of WVE-004 in C9-associated ALS and frontotemporal dementia after the therapy failed to show any clinical benefit in a mid-stage trial.

• Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial

  5/24/2023

  Immutep Limited today announces new encouraging clinical data in 1st line non-small cell lung cancer from INSIGHT-003, an investigator-initiated Phase I trial conducted by the Frankfurt Institute of Clinical Cancer Research IKF.

• Lassen Therapeutics Presents Phase I Data on LASN01, an IL-11 Receptor-Blocking Antibody for Treatment of Pulmonary Fibrosis, at the American Thoracic Society 2023 Annual Meeting

  5/24/2023

  Lassen Therapeutics presented new preclinical and Phase I data of LASN01 for treatment of pulmonary fibrosis, at today’s American Thoracic Society (ATS) Annual Meeting being held in Washington DC.

• Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial

  5/24/2023

  Cybin Inc. today announced that the first participants have been dosed with CYB004 in its ongoing three-part Phase 1 clinical trial evaluating intravenous N,N-dimethyltryptamine (“IV DMT”) and CYB004 in healthy volunteers.

• Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI)

  5/24/2023

  Peptilogics, a clinical-stage biotechnology company, today announced top-line interim data of PLG0206 in PJI patients from their ongoing Phase 1b trial.

• 4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting

  5/24/2023

  4D Molecular Therapeutics today announced an oral presentation of the interim data from the 4D-710 Phase 1/2 AEROW clinical trial for the treatment of cystic fibrosis lung disease at the European Cystic Fibrosis Society 46th Annual Meeting held in Vienna, Austria on June 7-10, 2023.

• PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD

  5/23/2023

  PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company received IND (Investigational New Drug) approval from the Korean MFDS (Ministry of Food and Drug Safety) to initiate a Phase I clinical trial of PMC-403, the Company's novel TIE2 agonistic antibody.

• MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

  5/23/2023

  MEI Pharma, Inc. today announced an update to the Phase 1 study evaluating voruciclib, an orally administered cyclin-dependent kinase 9 (“CDK9”) inhibitor, in patients with relapsed and refractory (“R/R”) acute myeloid leukemia (“AML”) or B-cell malignancies.

• HILLHURST BIOPHARMACEUTICALS ANNOUNCES COMPLETION OF LAST PATIENT LAST VISIT IN PHASE 1 CLINICAL TRIAL OF HBI-002

  5/23/2023

  Hillhurst Biopharmaceuticals, Inc. ("Hillhurst") today announced that the last participant has completed the study protocol of its U.S. Phase 1 clinical trial of HBI-002, an oral low dose carbon monoxide (CO) therapeutic candidate.

• Curium Announces Last Patient Enrolled in Their Phase 1/2 SOLAR Clinical Trial Imaging Men with Histologically-Proven Metastatic Prostate Cancer Using Copper Cu 64 PSMA I&T.

  5/23/2023

  Curium, a world leader in nuclear medicine, announced today that it has completed enrollment in its USA-led SOLAR Phase 1/2 study evaluating the safety, biodistribution, and image quality of Copper Cu64 PSMA I&T injection to detect metastatic prostate cancer in PET imaging.  

• Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

  5/23/2023

  Wave Life Sciences Ltd. today announced topline results from the Phase 1b/2a FOCUS-C9 study evaluating WVE-004 as an investigational treatment for C9orf72-associated amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (C9-ALS/FTD).